A nanoparticle containing poziotinib, its preparation method and application
By introducing carbonate ions into poziotinib nanoparticles to generate calcium carbonate and manganese carbonate nanocrystals and attaching biotin to the surface, the water solubility and targeting issues of poziotinib were resolved, achieving synergistic effects between chemotherapy and radiotherapy, improving treatment efficacy and reducing toxic side effects.
Patent Information
- Application Number
- CN202611636722.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-22
- Publication Date
- 2026-11-17
AI Technical Summary
Poziotinib has poor water solubility, low oral bioavailability, and lacks specificity in vivo distribution, leading to serious toxic side effects and making it difficult to achieve precise co-localization with radiotherapy and chemotherapy. Existing nanodelivery systems have loose structures and are easily dissociated in vivo, making it impossible to achieve long-term delivery and tumor-targeted enrichment.
Using sodium alginate as a framework, carbonate ions are introduced to generate calcium carbonate and manganese carbonate nanocrystals in situ with calcium and manganese ions, forming composite nanospheres. Biotin is then attached to the surface to achieve active targeted delivery, which can be combined with chemotherapy and radiotherapy for synergistic effects.
It improves the water solubility and bioavailability of poziotinib, enhances tumor targeting, reduces toxic side effects, achieves synergistic effects between chemotherapy and radiotherapy, and has a simple preparation method that is easy to scale up for production.
Smart Images

Figure CN123101701A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedicine, specifically to a nanoparticle containing poziotinib, its preparation method, and its application. Background Technology
[0002] In clinical oncology treatment, concurrent chemoradiotherapy integrates the local tumor control advantages of radiotherapy with the distant metastasis inhibition effect of chemotherapy. It is a standard treatment for locally advanced non-small cell lung cancer, head and neck squamous cell carcinoma, and other solid tumors, effectively improving local tumor control rates and prolonging patient survival. However, this therapy has significant limitations. First, the combination of radiotherapy and chemotherapy can lead to cumulative toxic side effects, significantly increasing the incidence of adverse reactions such as bone marrow suppression and radiation mucositis, reducing patient tolerance, and easily causing treatment interruption, dosage reduction, and weakening the treatment effect. Second, the distribution of chemotherapy drugs in the body lacks specificity, making it impossible to achieve precise spatiotemporal co-localization with the radiotherapy field, thus hindering the full realization of the synergistic anti-tumor effect of the two therapies. Therefore, developing a nanodelivery system that combines active tumor targeting with integrated radiotherapy and chemotherapy synergistic sensitization is a key direction for overcoming the clinical bottlenecks of concurrent chemoradiotherapy.
[0003] Poziotinib is a novel irreversible EGFR / HER2 dual-target tyrosine kinase inhibitor with significant efficacy against various solid tumors, including non-small cell lung cancer and breast cancer, making it an ideal drug for constructing synergistic radiotherapy and chemotherapy nanosystems. However, this drug suffers from poor water solubility and low oral bioavailability, and its distribution in vivo lacks specificity, easily causing serious toxic side effects such as bone marrow suppression and skin rashes, which greatly restricts its clinical translation and widespread application.
[0004] To improve the in vivo delivery of poziotinib, enhance its bioavailability, and reduce toxicity, current research utilizes nanocarriers to achieve controlled release and targeted delivery. Among these, sodium alginate, a natural anionic polysaccharide, exhibits excellent biocompatibility and drug-loading capacity, and can cross-link with metal ions such as manganese and calcium to form a gel network, improving drug dispersion stability. Simultaneously, manganese ions act as both a gel cross-linking component and a highly effective radiosensitizer, achieving a synergistic effect between chemotherapy and manganese ion radiosensitization. However, existing sodium alginate drug delivery systems have significant drawbacks. Pure sodium alginate-metal ion hydrogels have a loose structure and are prone to dissociation during in vivo circulation, failing to achieve long-term drug delivery and tumor-targeted enrichment. Sodium alginate-calcium carbonate nanoparticles suffer from weak active targeting capabilities, low tumor enrichment efficiency, complex preparation processes, and difficulty in large-scale production, thus failing to meet the clinical needs for precise co-targeting of radiotherapy and chemotherapy.
[0005] Biotin, a small-molecule vitamin, can specifically bind to biotin receptors highly expressed on the surface of tumor cell membranes. It possesses advantages such as low immunogenicity, high specificity, and strong tissue penetration, making it a high-quality active tumor-targeting ligand. Currently, no research has integrated poziotinib, sodium alginate, inorganic carbonates, and biotin to construct a targeted nanodelivery system, nor is there a structurally stable, highly targeted, and easily prepared multifunctional poziotinib radiosensitizing nanoformulation. Therefore, developing this novel nanodelivery system is of great value for improving the anti-tumor efficacy of poziotinib, reducing toxic side effects, and promoting clinical translation.
[0006] Currently, there are no reports on the combined construction of targeted nanodelivery systems using poziotinib, sodium alginate (SA), MnCO3 / CaCO3, and biotin. Therefore, developing a structurally stable poziotinib nanoformulation that is combined with radiotherapy, possesses active targeting capabilities, and has a simple preparation process has significant clinical translational value. To this end, this invention introduces carbonate ions (CO3-) 2- This allows it to react with calcium and manganese ions in situ to form calcium carbonate (CaCO3) and manganese carbonate (MnCO3) nanocrystals, creating composite nanospheres with regular morphology and higher mechanical strength, which are more suitable for long-term circulation and targeted delivery in vivo. Summary of the Invention
[0007] To address the technical problem of existing technologies lacking the ability to jointly construct targeted nanodelivery systems using poziotinib, sodium alginate (SA), MnCO3 / CaCO3, and biotin, this invention provides nanoparticles containing poziotinib, their preparation method, and applications to solve the aforementioned problem. This invention uses sodium alginate as a framework, encapsulating calcium and manganese ions before introducing carbonate ions (CO3). 2- This process allows the nanoparticles to react with calcium and manganese ions in situ to form calcium carbonate (CaCO3) and manganese carbonate (MnCO3) nanocrystals, creating composite nanospheres with regular morphology and higher mechanical strength, making them more suitable for long-term in vivo circulation and targeted delivery. Simultaneously, biotin is attached to the surface of the composite nanospheres, which can specifically bind to biotin receptors highly expressed on tumor cell membranes, enhancing the active targeted uptake efficiency of the nanoparticles. Furthermore, the composite nanoparticles provided by this invention also achieve synergistic effects between chemotherapy and radiotherapy, demonstrating significant clinical value.
[0008] The technical solution of this invention is as follows: In a first aspect, the present invention provides a method for preparing nanoparticles containing poziotinib, comprising: adding a mixed aqueous solution of calcium chloride and manganese chloride to a mixed aqueous solution of sodium alginate and poziotinib, then adding an aqueous solution of sodium carbonate to adjust the pH of the reaction solution to 9; collecting the solid and adding the solid to a biotin-PEG-Biotin (BPB) aqueous solution, and obtaining poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles after reaction; wherein the amount of poziotinib used is 200~300 g / mol based on the total amount of calcium chloride and manganese chloride; and the mass ratio of SA to poziotinib is 5:1.
[0009] Furthermore, in the mixed aqueous solution of calcium chloride and manganese chloride, Ca 2+ and Mn 2+ The concentrations were all 0.01 mol / L.
[0010] Furthermore, the concentration of the sodium carbonate aqueous solution is 0.01 mol / L.
[0011] Furthermore, the concentration of the biotin-PEG-biotin aqueous solution is 0.5 mg / mL.
[0012] Furthermore, the specific steps are as follows: (1) At room temperature and with stirring at 800 rpm, a mixed aqueous solution of calcium chloride and manganese chloride was slowly added dropwise to a mixed aqueous solution of sodium alginate and poziotinib, and stirred for 18-24 h; then, an aqueous solution of Na2CO3 was added dropwise to adjust the pH of the system to 9, and stirring was continued for 5 min. During this process, SA (sodium alginate) reacts with Ca... 2+ / Mn 2+ Ionic cross-linking occurs, and Ca 2+ Mn 2+ With CO3 2- The reaction generates MnCO3 / CaCO3 nanocrystals, which encapsulate poziotinib in a gel-inorganic hybrid network.
[0013] (2) Separate the reaction solution from step (1) into solid and liquid, collect the solid, and obtain poziotinib@SA-manganese carbonate-calcium carbonate.
[0014] (3) Add BPB solution to the poziotinib@SA-manganese carbonate-calcium carbonate collected in step (2), stir at 800 rpm for 18-24 h at room temperature, and then separate the solid and liquid to obtain poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles.
[0015] Furthermore, the dosage of poziotinib is 250 g / mol based on the total amount of calcium chloride and manganese chloride.
[0016] Furthermore, the amount of BPB used is 0.0625 g / g based on the mass of poziotinib.
[0017] Secondly, the present invention provides poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles obtained using the above method.
[0018] Thirdly, the present invention provides the application of the above-mentioned poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles in the preparation of a drug for the combined treatment of tumors with chemotherapy and radiotherapy.
[0019] Furthermore, the tumor is lung cancer.
[0020] The beneficial effects of this invention are as follows: (1) The poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles prepared in this invention are encapsulated in an SA-carbonate hybrid matrix, in which poziotinib is embedded in a hydrophilic gel-inorganic network, significantly improving its apparent solubility in water. Dynamic light scattering analysis showed that the hydrated particle size was controlled within the range of 150~250 nm, with an average value of 212.3±15.9 nm and a polydispersity (PDI) of 0.38±0.09, which is beneficial for long-term storage and intravenous injection.
[0021] (2) The poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles prepared in this invention introduce carbonate ions to generate calcium carbonate and manganese carbonate nanocrystals in situ, which are dispersed in the SA gel network. This solves the problem of loose structure and easy dissociation in vivo of simple SA-metal ion hydrogel, forming composite nanospheres with regular morphology and higher mechanical strength, which are more suitable for long-term circulation and targeted delivery in vivo.
[0022] (3) The poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles prepared in this invention have a biotin-PEG-biotin modified on their surface. The terminal biotin groups can specifically bind to biotin receptors highly expressed on tumor cell membranes, enhancing the active targeted uptake efficiency of the nanoparticles. Manganese ions in the hydrogel network are not only structural components but also recognized natural radiosensitizers. This invention co-delivers poziotinib with manganese ions, providing an ideal platform for combined radiotherapy.
[0023] (4) The preparation method provided by the present invention is carried out in the aqueous phase throughout the process, without the need for organic solvents, at room temperature, simple to operate, easy to scale up for production, and in line with the concept of green pharmaceutical manufacturing. Attached Figure Description
[0024] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, for those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0025] Figure 1 This is a transmission electron microscope image of the nanoparticles prepared in Example 1 of the present invention.
[0026] Figure 2 This is a graph showing the changes in particle size and zeta potential of the nanoparticles prepared in Example 1 of this invention during storage at 4°C for 15 days.
[0027] Figure 3 This is a fluorescence microscope image of the nanoparticles prepared in Example 1 of this invention after co-incubation with A549 cells. In the image, A is a bright-field image from a fluorescence microscope, and B is a fluorescence image from a fluorescence microscope.
[0028] Figure 4 This is a fluorescence microscope image of the nanoparticles prepared in Example 1 of this invention after co-incubation with BEAS-2B cells. In the image, A is a bright-field image from a fluorescence microscope, and B is a fluorescence image from a fluorescence microscope.
[0029] Figure 5 This is a comparative diagram showing the inhibitory effect of poliotinib@SA-manganese carbonate / calcium carbonate@BPB nanoparticles combined with radiotherapy on LLC cells in Example 6 of this invention.
[0030] Figure 6 This is a graph showing the effect of different dosages of poziotinib@SA-manganese carbonate / calcium carbonate@BPB nanoparticles combined with radiotherapy on LLC cell viability in Example 7 of this invention. In this graph, A represents the effect on LLC cell viability without combined radiotherapy; B represents the effect on LLC cell viability with combined 2Gy radiotherapy. Detailed Implementation
[0031] To enable those skilled in the art to better understand the technical solutions of this invention, the technical solutions of the embodiments of this invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this invention, and not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the scope of protection of this invention.
[0032] The preparation methods for the various solvents used in Examples 1-3 are as follows: 1. Mixed aqueous solution of calcium chloride and manganese chloride: Weigh 0.055g of anhydrous calcium chloride and 0.063g of manganese chloride, place them in a 50mL centrifuge tube, add 50mL of ultrapure water, and obtain a mixed aqueous solution of calcium chloride and manganese chloride with calcium ion and manganese ion concentrations of 0.01M.
[0033] 2. Mixed aqueous solution of sodium alginate and poziotinib: Weigh 50 mg of sodium alginate and 10 mg of poziotinib, add 50 mL of ultrapure water, and stir at 800 rpm for 30 min at room temperature to mix them evenly, so as to obtain a mixed aqueous solution of sodium alginate and poziotinib.
[0034] 3. Sodium carbonate aqueous solution: Weigh 0.53g of Na2CO3 and add 50mL of ultrapure water to obtain a 0.1M Na2CO3 aqueous solution.
[0035] 4. Biotin-PEG-Biotin aqueous solution: Weigh 25 mg of BPB (molecular weight approximately 3400 Da), add 50 mL of ultrapure water to obtain a 0.5 mg / mL BPB aqueous solution.
[0036] Example 1 The specific method for preparing poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles is as follows: (1) Measure 2 mL of a mixed aqueous solution of calcium chloride and manganese chloride and slowly add it dropwise to a mixed aqueous solution of sodium alginate and poziotinib at room temperature and stirring at 800 rpm. Continue stirring for 24 h. Then add 1 mL of sodium carbonate aqueous solution dropwise to adjust the pH of the reaction system to 9 and continue stirring for 5 min.
[0037] (2) Centrifuge the mixture obtained in step (1) at 8000 rpm for 1 h at 4 °C and collect the supernatant. Centrifuge the supernatant at 23000 rpm for 2 h at 4 °C and collect the solid.
[0038] (3) Take the solid obtained in step (2), resuspend it at a ratio of 1 mL BPB solution for every 10 mg of precipitate, and stir at 800 rpm for 24 h at room temperature to obtain poziotinib@SA-manganese carbonate / calcium@BPB nanoparticle solution.
[0039] The prepared poziotinib@SA-manganese carbonate / calcium@BPB nanoparticle solution was subjected to various tests. The obtained solution was a milky white, homogeneous colloidal solution. Dynamic light scattering analysis showed an average hydrated particle size of 212.3 ± 15.9 nm, a PDI of 0.38 ± 0.09, and a Zeta potential of -27.5 ± 2.1 mV. These data indicate that the method of this invention can successfully prepare nanoparticles with uniform particle size and stable dispersion.
[0040] Separately, a solution of poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles was dropped onto a copper mesh carbon film. After natural drying, the morphology was observed using a transmission electron microscope (accelerating voltage 80 kV). The results are as follows: Figure 1 As shown. From Figure 1As can be seen, the nanoparticles are regularly spherical, without aggregation or breakage, indicating that the method of this invention has successfully prepared spherical nanoparticles with stable morphology and structure. This regularly spherical structure is beneficial for reducing the recognition by the phagocytic system in vivo, prolonging blood circulation time, and improving the passive targeting and enrichment ability of tumor tissue.
[0041] Example 2 The specific method for preparing poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles is as follows: (1) Measure 2 mL of a mixed aqueous solution of calcium chloride and manganese chloride and slowly add it dropwise to a mixed aqueous solution of sodium alginate and poziotinib at room temperature and stirring at 800 rpm. Continue stirring for 24 h. Then add 1 mL of sodium carbonate aqueous solution dropwise to adjust the pH of the reaction system to 9 and continue stirring for 5 min.
[0042] (2) Centrifuge the mixture obtained in step (1) at 8000 rpm for 1 h at 4 °C and collect the supernatant. Centrifuge the supernatant at 23000 rpm for 2 h at 4 °C and collect the solid.
[0043] (3) Take the solid obtained in step (2), resuspend it at a ratio of 1 mL BPB solution for every 10 mg of precipitate, and stir at 800 rpm for 24 h at room temperature to obtain poziotinib@SA-manganese carbonate / calcium@BPB nanoparticle solution.
[0044] Example 3 The specific method for preparing poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles is as follows: (1) Measure 2 mL of a mixed aqueous solution of calcium chloride and manganese chloride and slowly add it dropwise to a mixed aqueous solution of sodium alginate and poziotinib at room temperature and 800 rpm. Continue stirring for 24 h. Then add 1 mL of sodium carbonate aqueous solution dropwise to adjust the pH of the reaction system to 9 and continue stirring for 5 min.
[0045] (2) Centrifuge the mixture obtained in step (1) at 8000 rpm for 1 h at 4 °C and collect the supernatant. Centrifuge the supernatant at 23000 rpm for 2 h at 4 °C and collect the solid.
[0046] (3) Take the solid obtained in step (2), resuspend it at a ratio of 1 mL BPB solution for every 10 mg of precipitate, and stir at 800 rpm for 24 h at room temperature to obtain poziotinib@SA-manganese carbonate / calcium@BPB nanoparticle solution.
[0047] Example 4 The poziotinib@SA-manganese carbonate / calcium@BPB nanoparticle suspension prepared in Example 1 was stored at 4°C. Samples were taken on days 1, 2, 3, 4, 5, 7, 9, 11, and 15 to determine particle size and zeta potential. The particle size and zeta potential changes during the 15-day storage at 4°C are shown in the figure below. Figure 2 As shown. From Figure 2 As can be seen, the nanoparticles prepared in Example 1 did not exhibit significant changes in hydrated particle size and Zeta potential during a 15-day storage period. This demonstrates that the nanoparticles prepared in this invention possess excellent short-term storage stability at 4°C, maintaining constant particle size and surface charge without aggregation, sedimentation, or degradation. This characteristic ensures the consistency of the physicochemical properties of the nanoparticles during storage and transportation, providing reliable quality assurance for their subsequent cell experiments, in vivo animal studies, and potential clinical translation.
[0048] Example 5 The poziotinib@SA-manganese carbonate / calcium@BPB nanoparticle suspension prepared in Example 1 was conjugated with FITC to visualize the nanoparticle distribution. Human non-small cell lung cancer A549 cells (highly expressing biotin receptor) and normal human lung epithelial BEAS-2B cells were seeded on opposite sides of a two-segmented cell culture dish at a density of 3 × 10⁻⁶ cells / mL. 4 The nanoparticles were collected at a concentration of 50 μg / mL and allowed to adhere overnight. The separator was then removed, and FITC-labeled nanoparticles were added to a final concentration of 50 μg / mL. The mixture was circulated at 10 mL / min for 1 hour using a liquid circulation pump, followed by observation under a fluorescence microscope. Results are as follows: Figure 3 and Figure 4 As shown. From Figure 3 As can be seen, A549 cells exhibit strong green fluorescence; from Figure 4 As can be seen, BEAS-2B cells showed almost no fluorescence signal. This indicates that the poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles prepared in this invention can actively target tumor cells that highly express biotin receptors, achieving specific binding and endocytosis, while exhibiting no significant non-specific adhesion to normal cells, thus confirming its excellent active targeting ability.
[0049] Example 6 Testing the efficacy of poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles combined with radiotherapy in inhibiting lung cancer LLC cells. 1. Experimental Grouping (1) Poziotinib control group (P): Poziotinib concentration 0.344 μg / mL; (2) Poziotinib + radiotherapy combination group (P+RF): Poziotinib concentration 0.344 μg / mL + 2 Gy X-ray irradiation; (3) Poziotinib@SA-manganese carbonate / calcium carbonate@BPB nanoparticle group (NP): The concentration of the test solution for poziotinib@SA-manganese carbonate-calcium carbonate@BPB nanoparticles was 100 μg / mL; (4) Poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles + radiotherapy combination group (NP+RF): Poziotinib@SA-manganese carbonate-calcium carbonate@BPB nanoparticles concentration 100μg / mL + 2Gy X-ray irradiation.
[0050] 2. Test methods Poziotinib test solution with a concentration of 0.344 μg / mL and poziotinib@SA-manganese carbonate / calcium carbonate@BPB nanoparticle test solution with a concentration of 100 μg / mL were prepared respectively. The concentration of poziotinib in both poziotinib and poziotinib@SA-manganese carbonate / calcium carbonate@BPB nanoparticles was 0.7 nmol / mL. Mouse lung cancer LLC cells were treated for 24 hours in the four experimental groups. Experimental groups (2) and (4) were irradiated with 2 Gy X-rays in addition to treating mouse lung cancer LLC cells. Cell viability was determined by the CCK-8 assay. The test results are as follows. Figure 5 As shown. From Figure 5 As can be seen, without combined radiotherapy, the cell survival rate in the poziotinib control group was 97.39%±5.69%, while the cell survival rate in the poziotinib@SA-manganese carbonate / calcium@BPB nanoparticle group was 59.63%±3.88%. After combined 2Gy radiotherapy, the cell survival rate in the poziotinib control group was 95.72%±4.49%, while the cell survival rate in the poziotinib@SA-manganese carbonate / calcium@BPB nanoparticle group was 44.14%±3.91%. The above comparison shows that when poziotinib is administered alone, there is no significant difference in cell survival rate before and after combined radiotherapy, indicating that poziotinib itself does not possess radiosensitizing ability. However, poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles exhibited superior cell-killing effects compared to free poziotinib even without combined radiotherapy, which is attributed to the active targeting effect mediated by its surface biotin modification, enhancing the efficient uptake of the drug by tumor cells. After combined radiotherapy, the cell survival rate of the nanoparticle group was further significantly reduced, confirming that the manganese ions in the nanoparticles of this invention played an effective radiosensitizing role and successfully achieved the synergistic effect of chemotherapy-radiotherapy.
[0051] Example 7 Testing the efficacy of different doses of poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles combined with radiotherapy in inhibiting lung cancer LLC cells. Poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles were prepared at different concentrations of 1 μg / mL, 10 μg / mL, 100 μg / mL, 500 μg / mL, 1000 μg / mL, and 2000 μg / mL, and then used to treat mouse lung cancer LLC cells for 24 hours. A combined 2 Gy X-ray irradiation group and a non-irradiated group were also included. Cell viability was measured using the CCK-8 assay. The test results are as follows: Figure 6 As shown. From Figure 6 As can be seen from Figure A, the half-maximal inhibitory concentration (IC50) in the group without combined radiotherapy was significantly lower. 50 The concentration was 130.40 μg / mL; from Figure 6 As can be seen from B, the IC of the combined 2Gy radiotherapy group 50 The concentration was 68.87 μg / mL. These data indicate that combined radiotherapy can significantly reduce the IC50 of nanoparticles on LLC cells. 50 The value, which enhances the sensitivity of tumor cells to drugs, further confirms that the poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles prepared in this invention achieve a synergistic anti-tumor effect of chemotherapy-radiotherapy.
[0052] Although the present invention has been described in detail with reference to the accompanying drawings and preferred embodiments, the present invention is not limited thereto. Various equivalent modifications or substitutions can be made to the embodiments of the present invention by those skilled in the art without departing from the spirit and essence of the invention, and such modifications or substitutions should all be within the scope of the present invention. Any variations or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention should also be covered within the protection scope of the present invention.
Claims
1. A method for preparing nanoparticles containing poziotinib, characterized in that, A mixed aqueous solution of calcium chloride and manganese chloride was added to a mixed aqueous solution of sodium alginate and poziotinib, followed by the addition of an aqueous solution of sodium carbonate to adjust the pH of the reaction solution to 9. After collecting the solid, the solid was added to a biotin-PEG-biotin aqueous solution, and poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles were obtained after the reaction. The amount of poziotinib used was 200-300 g / mol based on the total amount of calcium chloride and manganese chloride. The mass ratio of SA to poziotinib was 5:
1.
2. The preparation method according to claim 1, characterized in that, In the mixed aqueous solution of calcium chloride and manganese chloride, Ca 2+ and Mn 2+ The concentrations were all 0.01 mol / L.
3. The preparation method according to claim 1, characterized in that, The concentration of the biotin-PEG-biotin aqueous solution is 0.5 mg / mL.
4. The preparation method according to any one of claims 1-3, characterized in that, The specific steps are as follows: (1) At room temperature and with stirring at 800 rpm, a mixed aqueous solution of calcium chloride and manganese chloride was added dropwise to a mixed aqueous solution of sodium alginate and poziotinib and stirred for 18-24 h; then Na2CO3 aqueous solution was added dropwise to adjust the pH of the system to 9 and stirring was continued for 5 min. (2) Separate the reaction solution from step (1) into solid and liquid phases and collect the solid. (3) Add BPB solution to the solid collected in step (2), stir at 800 rpm for 18-24 h at room temperature, and then separate the solid and liquid to obtain poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles.
5. The preparation method according to claim 4, characterized in that, The dosage of poziotinib is 250 g / mol, calculated as the total amount of calcium chloride and manganese chloride.
6. The preparation method according to claim 4, characterized in that, The dosage of BPB is 0.0625 g / g based on the mass of poziotinib.
7. A poziotinib@SA-manganese carbonate / calcium@BPB nanoparticle obtained using the preparation method described in claim 5 or 6.
8. The use of poziotinib@SA-manganese carbonate / calcium@BPB nanoparticles as described in claim 7 in the preparation of a medicament for the combined chemotherapy and radiotherapy for the treatment of tumors.
9. The application as described in claim 8, characterized in that, The tumor is lung cancer.
